Skip to main content

Advertisement

SpringerLink
Log in

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tefferi A, Vardiman JW . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22.

    Article  CAS  Google Scholar 

  2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

    Article  CAS  Google Scholar 

  3. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.

    Article  CAS  Google Scholar 

  4. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.

    Article  CAS  Google Scholar 

  5. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.

    Article  CAS  Google Scholar 

  6. Monaghan KA, Khong T, Burns CJ, Spencer A . The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia 2011; 25: 1891–1899.

    Article  CAS  Google Scholar 

  7. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A . CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009; 23: 1441–1445.

    Article  CAS  Google Scholar 

  8. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010; 115: 5232–5240.

    Article  CAS  Google Scholar 

  9. Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013; 27: 1322–1327.

    Article  CAS  Google Scholar 

  10. Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B et al. What are RBC-transfusion-dependence and -independence? Leuk Res 2011; 35: 8–11.

    Article  CAS  Google Scholar 

  11. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497–1503.

    Article  CAS  Google Scholar 

  12. Gupta V, Mesa RA, Deininger MW, Rivera CE, Sirhan S, Brachmann CB et al. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica 2017; 102: 94–102.

    Article  CAS  Google Scholar 

  13. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117–1127.

    Article  CAS  Google Scholar 

  14. Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Tefferi A . Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. Leukemia 2015; 29: 498–500.

    Article  CAS  Google Scholar 

  15. Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol 2017; 35: 3844–3850.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Medical writing support was provided by Claire Danielle, PhD, and Ewa Wandzioch, PhD, of AlphaBioCom, LLC (King of Prussia, PA, USA) and funded by Gilead Sciences, Inc. (Foster City, CA, USA).

JG received research funding for the conduct of the trial. VG received research funding through institution from Incyte and Novartis, served on advisory board of Novartis, and received honorarium from Novartis and Incyte. JK, JAM, LS are employees of Gilead Sciences, Inc. The remaining authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, Rochester, MN, USA

    A Pardanani & A Tefferi

  2. Stanford Cancer Institute, Stanford, CA, USA

    J Gotlib

  3. Clinical Hematology & BMT, Royal Melbourne Hospital, and University of Melbourne, Parkville, Australia

    A W Roberts

  4. Deparment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA

    M Wadleigh

  5. Division of Hematology, Jewish General Hospital, Montreal, QC, Canada

    S Sirhan

  6. Gilead Sciences, Inc, Foster City, CA, USA

    J Kawashima, J A Maltzman & L Shao

  7. Princess Margaret Cancer Centre, Toronto, ON, Canada

    V Gupta

Authors
  1. A Pardanani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Gotlib
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A W Roberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Wadleigh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Sirhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Kawashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J A Maltzman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. V Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Tefferi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Pardanani.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pardanani, A., Gotlib, J., Roberts, A. et al. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Leukemia 32, 1034–1037 (2018). https://doi.org/10.1038/leu.2017.330

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2017.330

  • Springer Nature Limited

This article is cited by

Search

Navigation